📊 CLSDQ Key Takeaways
Investment Thesis
Clearside Biomedical faces severe financial distress with negative stockholders' equity of -$54.0M, indicating liabilities exceed assets by a significant margin. The company is burning cash rapidly with -$16.0M operating cash flow against only $6.8M in cash reserves, providing minimal runway. Revenue has collapsed 79.8% YoY while operating losses exceed -$15.8M, demonstrating a non-viable business model at current scale.
CLSDQ Strengths
- Current ratio of 2.98x provides short-term liquidity buffer despite negative equity
- Relatively low long-term debt of $385.0K limits additional leverage burden
- Pharmaceutical sector positioning in specialized treatments if development succeeds
CLSDQ Risks
- Negative stockholders' equity of -$54.0M indicates technical insolvency and high bankruptcy risk
- Cash burn rate of -$16.0M annually against $6.8M cash implies runway of less than 5 months
- Severe revenue decline of -79.8% YoY signals complete loss of commercial traction
- Negative operating margin of -523.1% and net margin of -618.3% demonstrate unsustainable unit economics
- Zero insider buying in last 90 days and no evidence of strategic confidence
Key Metrics to Watch
- Monthly cash burn rate and cash position deterioration
- Revenue stabilization or evidence of new commercial contracts
- Stockholders' equity trajectory and capital restructuring plans
- Operating cash flow improvement toward sustainability threshold
CLSDQ Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 2.98x current ratio provides a solid financial cushion.
CLSDQ Profitability Ratios
CLSDQ vs Healthcare Sector
How Clearside Biomedical, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CLSDQ Balance Sheet & Liquidity
CLSDQ 5-Year Financial Trend
5-Year Trend Summary: Clearside Biomedical, Inc.'s revenue has shown modest growth of 4% over the 5-year period. The most recent EPS of $-0.55 indicates the company is currently unprofitable.
CLSDQ Growth Metrics (YoY)
CLSDQ Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $201.0K | -$4.5M | $-1.14 |
| Q2 2025 | $90.0K | -$4.5M | $-0.06 |
| Q1 2025 | $230.0K | -$8.2M | $-0.11 |
| Q3 2024 | $859.0K | -$7.6M | $-0.10 |
| Q2 2024 | $90.0K | -$7.6M | $-0.10 |
| Q1 2024 | $4.0K | -$9.3M | $-0.15 |
| Q3 2023 | $266.0K | -$7.6M | $-0.13 |
| Q2 2023 | $384.0K | -$7.6M | $-0.13 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CLSDQ Capital Allocation
CLSDQ SEC Filings
Access official SEC EDGAR filings for Clearside Biomedical, Inc. (CIK: 0001539029)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CLSDQ
What is the AI rating for CLSDQ?
Clearside Biomedical, Inc. (CLSDQ) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CLSDQ's key strengths?
Current ratio of 2.98x provides short-term liquidity buffer despite negative equity. Relatively low long-term debt of $385.0K limits additional leverage burden.
What are the risks of investing in CLSDQ?
Negative stockholders' equity of -$54.0M indicates technical insolvency and high bankruptcy risk. Cash burn rate of -$16.0M annually against $6.8M cash implies runway of less than 5 months.
What is CLSDQ's revenue and growth?
Clearside Biomedical, Inc. reported revenue of $3.0M.
Does CLSDQ pay dividends?
Clearside Biomedical, Inc. does not currently pay dividends.
Where can I find CLSDQ SEC filings?
Official SEC filings for Clearside Biomedical, Inc. (CIK: 0001539029) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CLSDQ's EPS?
Clearside Biomedical, Inc. has a diluted EPS of $-3.61.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.